Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
A phase 1/2 trial of Elironrasib, Daraxonrasib in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Overview
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors is a phase 1/2 interventional study registered as NCT06128551 by Revolution Medicines, Inc., with 534 participants planned, started 2023-11-14 and due to reach its primary completion in 2028-12. Interventions recorded: Elironrasib, Daraxonrasib. Conditions listed: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Pancreatic ductal adenocarcinoma.
- TrialStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Small-cell lung cancer.
- TrialStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Small-cell lung cancer.
- TrialStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- TrialStudy of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut
Shares Revolution Medicines, Daraxonrasib, Pancreatic ductal adenocarcinoma.